Molecular Diagnosis of Lung Cancer

Savelina L. Popovska; Tereza B. Dineva; Polina D. Damyanova

doi:10.1515/jbcr-2017-0016

.blurhash-client-img { display: none !important; }

Molecular Diagnosis of Lung Cancer

Journal of Biomedical and Clinical Research

Volume 10 (2017): Issue 2 (December 2017)

By: Savelina L. Popovska, Tereza B. Dineva and Polina D. Damyanova

Open Access

|Jun 2018

Abstract

Lung cancer is still the leading cancer-related cause of death with a high incidence rate in the whole world. Treatment options – surgery, radiotherapy, and chemotherapy, depending on the stage of the disease. During the last decade, many molecular alterations were discovered that led to impressive changes in treatment. Personalized approaches, including target therapies with specific inhibitor drugs, became a part of the standard therapies. This article reviews current molecular biomarkers used in clinical practice to treat lung cancer patients.

References

1. Centers for Disease Control and Prevention. Compressed mortality file 1999-2011 [CD- ROM]. Atlanta: National Center for Health Statistics; 2014.
Search in Google Scholar Back to article
2. National Oncological Hospital, Bulgarian National Cancer Resistry. Cancer Incidence in Bulgaria. Sofia: Paradigma; 2014, 170 p.
Search in Google Scholar Back to article
3. Chilingirova N, Balabanski L, Toncheva D, Kurteva G, Damyanov D, Chilingirov P. Identifying the genetic landscape of squamous cell carcinoma (SCC) and adenosquamous carcinoma (ASC) of the lung using next- generation sequencing (NGS). Ann Oncol. 2015;26 Suppl: i1- i5.10.1093/annonc/mdv043.16
Search in Google Scholar Back to article
4. Chilingirova N, Balabanski L, Kurteva G, Toncheva D, Damyanov D, Chilingirov P. Detection of driver mutation heterogeneity in patients with non-small cell lung cancer (NSCLC) using next generation sequencing (NGS). EJC. 2015;51 Suppl 3:S612-S613.10.1016/S0959-8049(16)31692-6
Search in Google Scholar Back to article
5. Chilingirova N, Balabanski L, Ivanov S, Vazharova R, Toncheva D, Kurteva G. Detection of extensive driver mutation heterogeneity in 5 Bulgarian patients with adenosquamous carcinoma of the lung. Eur J Hum Genet. 2015;23(1).
Search in Google Scholar Back to article
6. Chilingirova N. [Non-small cell lung cancer in the era of precision medicine]. INSPIRO. 2017;2(40):13-7. Bulgarian.
Search in Google Scholar Back to article
7. Chilingirova N. [Role of tumor markers]. Rheumatology. 2013;21(1). Bulgarian.
Search in Google Scholar Back to article
8. Chilingirova N, Kurteva G, Toncheva D. [Lung Cancer and genetics]. Oncology. 2015; 4:40. Bulgarian.
Search in Google Scholar Back to article
9. Chilingirova N. [Lung Cancer - an overview]. Zdraven Navigator. 2017;3:2-4. Bulgarian.
Search in Google Scholar Back to article
10. Rousseau B, Jacquot, C, Le Palabe J, Malleter M, Tomasoni C, Boutard T, et al. TP53 transcription factor for the NEDD9/HEF1/Cas-L gene: potential targets in Non-Small Cell Lung Cancer treatment. Sci Rep. 2015 May 26;5:10356.10.1038/srep10356
Search in Google Scholar Back to article
11. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003;3(6):459- 65.10.1038/nrc1097
Search in Google Scholar Back to article
12. Cardarella S, Ogino A, Nishino M, Butaney M, Shen J, Lydon C et al. Clinical, pathologic and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 2013;19(16):4532-40.10.1158/1078-0432.CCR-13-0657
Search in Google Scholar Back to article
13. Marchetti A, Felicioni L, Malatesta S, Grazia Sciarrotta M, Guetti L, Chella A, et al. Clinical features and outcome of patients with non-small- cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574-9.10.1200/JCO.2011.35.9638
Search in Google Scholar Back to article
14. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005;5(5):341-4.10.1038/nrc1609
Search in Google Scholar Back to article
15. Popovska S, Chilingirova N, Dineva T, Kamburova Z. Prevalence of epidermal growth factor receptor (EGFR) gene mutations in non-small cell lung cancer (NSCLC) in Bulgarian population, J Thorac Oncol. 2016;11(4);Suppl:S128-S129.10.1016/S1556-0864(16)30273-8
Search in Google Scholar Back to article
16. Lampaki S, Lazaridis G, Zarogoulidis K, Kioumis I, Papaiwannou A, Tsirgogianni K, et al. Defining the role of tyrosine kinase inhibitors in early stage non-small cell lung cancer. J Cancer. 2015;6(6):568-74.10.7150/jca.11893443994326000049
Search in Google Scholar Back to article
17. Vanderbilt-Ingram Cancer Center. Molecular Profiling of Lung Cancer [Internet]. Nashville; c2016. [cited 2018 Febr 18]. Available from: https://www.mycancergenome.org/content/disease/lung-cancer/.
Search in Google Scholar Back to article
18. Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390-401.10.1016/j.apsb.2015.07.001462944226579470
Search in Google Scholar Back to article
19. Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240-7.10.1158/1078-0432.CCR-12-2246363027023470965
Search in Google Scholar Back to article
20. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel– Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. N Engl J Med. 2006;355(24):2542-50.10.1056/NEJMoa06188417167137
Search in Google Scholar Back to article
21. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol. 2010;21(9):1804-9.10.1093/annonc/mdq020292499220150572
Search in Google Scholar Back to article
22. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227-34.10.1200/JCO.2007.14.546619188680
Search in Google Scholar Back to article
23. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist. 2009;14(3):253-63.10.1634/theoncologist.2008-023219221167
Search in Google Scholar Back to article
24. Chilingirova N, Hammoudeh Z, Balabanski L, Ivanov S, Vazharova R, Nikolova D, et al. TruSight Cancer Sequencing Panel reveals pharmacogenetic variants associated with sensitivity to chemotherapy in lung cancer. memo-Magazine of European Medical Oncology. 2016; 9(1):30-8.10.1007/s12254-015-0244-2
Search in Google Scholar Back to article
25. Chilingirova N, Kurteva G, Toncheva D. TruSight Cancer Sequencing Panel for detecting of driver mutation heterogeneity and pharmacogenetic variants associated with sensitivity to chemotherapy in patients with non-small cell lung cancer (NSCLC). Proceedings of the 8th National Conference for Rare Diseases and Orphan Drugs & 12th Balkan Congress of Human Genetics; 2017 Sept 8-10; Plovdiv, Bulgaria: Abstract book, p.67.
Search in Google Scholar Back to article
26. Chilingirova N, Hammoudeh Z, Balabanski L, Ivanov S, Vazharova R, Nesheva D, et al. Pharmacogenomic study of non-small cell lung cancer. Eur J Hum Genet. 2015;23(1).
Search in Google Scholar Back to article
27. Chilingirova N, Chilingirov N. [Pharmacogenetics and drug resistance in oncology]. Rheumatology. 2017 Dec: 35. Bulgarian.
Search in Google Scholar Back to article
28. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S, et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin- treated advanced non-small cell lung cancer patients. Clin Cancer Res. 2008;14(6):1797-3.10.1158/1078-0432.CCR-07-136418347182
Search in Google Scholar Back to article
29. Chilingirova N, Chilingirov N. [Therapy related side effects in the treatment of lung cancer]. Rheumatology. 2017 Dec; 1:47. Bulgarian.
Search in Google Scholar Back to article
30. Chilingirova N. [Mucositis]. In: [Kurteva G, Trifonova I, editors. Treatment related side effects]. Sofia; 2017. p. 149-163. Bulgarian.
Search in Google Scholar Back to article
31. Hrstka R, Coates PJ, VoJtesek B. Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med. 2009;13(3):440-53.10.1111/j.1582-4934.2008.00634.x382250719379143
Search in Google Scholar Back to article
32. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet. 2003;33(3):357- 65.10.1038/ng109312567188
Search in Google Scholar Back to article
33. Liu L, Wu C, Wang Y, Zhong R, Duan S, Wei S, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6(11):1793-800.10.1097/JTO.0b013e318227227321841506
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.1515/jbcr-2017-0016 | Journal eISSN: 1313-9053

Journal RSS Feed

Language: English

Page range: 98 - 103

Submitted on: Jan 16, 2018

Accepted on: Feb 27, 2018

Published on: Jun 30, 2018

Published by: Sciendo

In partnership with: Paradigm Publishing Services

Publication frequency: 2 issues per year

Keywords:

molecular biomarkers,

Related subjects:

Clinical medicine, other,

© 2018 Savelina L. Popovska, Tereza B. Dineva, Polina D. Damyanova, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 10 (2017): Issue 2 (December 2017)